Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Lamivudine

Lamivudine

Lamivudine: A nucleoside reverse transcriptase inhibitor used to treat HIV infection and hepatitis B.
This AI-driven platform helps optimize your Lamivudine research by enabling you to easily locate protocols from literature, preprints, and patents, while utilizing AI-comparisons to identify the best protocols and products.
Streamline your Lamivudine research with PubCompare.ai's powerful tools and discover new insights to advance your work.

Most cited protocols related to «Lamivudine»

1
Early ART in HIV-Infected Infants
Cited 50 times
The Children with HIV Early Antiretroviral Therapy (CHER) trial is a phase 3, randomized, open-label trial conducted by the Comprehensive International Program for Research in AIDS — South Africa in collaboration with the Medical Research Council Clinical Trials Unit, United Kingdom, and the Division of AIDS (DAIDS) of the National Institutes of Health (NIH). The study is being conducted in two centers in South Africa: the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, in Soweto, and the Children's Infectious Diseases Clinical Research Unit, Tygerberg Children's Hospital, in Cape Town.
We enrolled infants 6 to 12 weeks of age who had HIV infection (defined by a positive polymerase-chain-reaction [PCR] test for HIV-1 DNA and a plasma HIV-1 RNA level on PCR of >1000 copies per milliliter) and a CD4 percentage of 25% or more. Exclusion criteria are listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org. Infants were randomly assigned to receive one of three treatments: early limited antiretroviral therapy for 96 weeks, early limited antiretroviral therapy for 40 weeks, or deferred therapy. Immunologic criteria for initiating antiretroviral therapy in the deferred-therapy group or reinitiating antiretroviral therapy in the early-therapy groups were a CD4 percentage of less than 20%5 or, in the case of children younger than 12 months, a CD4 percentage of less than 25% or a CD4 count of less than 1000 cells per cubic millimeter, according to World Health Organization (WHO) guidelines updated in 2006.6 Clinical criteria for initiating or reinitiating antiretroviral therapy7 were Centers for Disease Control and Prevention (CDC) stage C or investigator-selected (severe) stage B events (see the Supplementary Appendix), including symptomatic lymphoid interstitial pneumonitis, bronchiectasis, nephropathy, cardiomyopathy, and failure to thrive. GlaxoSmithKline provided lamivudine and zidovudine, and the South African Department of Health provided lopinavir–ritonavir. Written informed consent was obtained from the parents or legal guardians of all the infants. The authors vouch for the completeness and accuracy of the data.
Violari A., Cotton M.F., Gibb D.M., Babiker A.G., Steyn J., Madhi S.A., Jean-Philippe P, & McIntyre J.A. (2008). Early Antiretroviral Therapy and Mortality among HIV-Infected Infants. The New England journal of medicine, 359(21), 2233-2244.
Publication 2008
Acquired Immunodeficiency Syndrome Bronchiectasis Cardiomyopathies CD4+ Cell Counts Cells Child Communicable Diseases Cuboid Bone Early Therapy Failure to Thrive Group Therapy HIV-1 HIV Infections Infant Kidney Diseases Lamivudine Legal Guardians lopinavir-ritonavir drug combination Lymphoid Interstitial Pneumonia Parent Plasma Polymerase Chain Reaction Southern African People Therapeutics Youth Zidovudine
2
Pneumococcal Vaccine Response in HIV-Exposed Infants
Cited 28 times
The study enrolled a priori four groups of children aged 6 to 12 weeks. These included 2 groups of HIV infected infants, co-enrolled from the Children with HIV Early Antiretroviral (CHER) Study in South Africa, 5 (link) with CD4+ T-lymphocyte cells ≥25% randomized to initiate ART immediately (HIV+/ART+ group); or ART was initiated when clinically or immunologically indicated (HIV+/ART− Group). 6 The ART regimen included zidovudine, lamivudine and lopinavir/ritonavir. Additionally, two cohorts of HIV non-infected infants were prospectively enrolled in parallel to the HIV infected children including: i. infants born to HIV infected mothers who were HIV PCR (Roche Amplicor Version 1.5 RNA PCR) negative at baseline and one month after the third dose of Vaccine (M+/I−) and ii. infants born to mothers seronegative for HIV after 24 weeks of gestational age during pregnancy and who were HIV ELISA seronegative at study-enrolment (i.e. M−/I−).
Additional participant-eligibility criteria included absence of intercurrent illness within 72 hours of enrolment, no Grade 3 or 4 clinical or laboratory toxicity as per DAIDS Pediatric Adverse Experiences,7 birth weight of at least 2000 grams, participation in the CHER study for HIV infected infants, absence of receipt of any blood products prior to study entry, any immunomodulating medication for more than two weeks within one week of possible enrolment
Infants were enrolled between April 2005 and June 2006 and scheduled to receive three doses of 7-valent pneumococcal conjugate vaccine (i.e. Prevnar®; Wyeth Vaccines, NJ, USA) at 6 to 12, 9 to 18 and 12 to 24 weeks of age. Infants received other scheduled childhood vaccines, included in the public immunization program, concurrently with Prenar®.
Immune response to the primary series of Vaccine was measured 3 to 6 weeks after the third dose using serum from venous blood which had been centrifuged, aliquotted and stored at –20 to −70°C until processing at the Respiratory and Meningeal Pathogens Research Unit (RMPRU), Johannesburg, South Africa. A standardized enzyme immunoassay (EIA), including adsorption with 22F polysaccharide, was used to test for vaccine-serotype specific capsular IgG antibody concentrations as described. 8 (link) 9 (link)
The functionality of the antibodies post vaccination was determined by opsonophagocytic killing assay (OPA) for serotypes 9V, 19F and 23F using differentiated HL-60 cells as described.8 (link) 10 (link) Lower antibody concentrations required for 50% killing activity on OPA is suggestive of superior antibody functional activity. Detectable killing activity on OPA was defined as a titer of ≥8.
For quality assurance, a quality control serum from a vaccinated volunteer was included on each plate. The coefficient of variation for the control sera were <40% for all serotypes.
Madhi S.A., Adrian P., Cotton M.F., McIntyre J.A., Jean-Philippe P., Meadows S., Nachman S., Käyhty H., Klugman K.P, & Violari A. (2010). Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. The Journal of infectious diseases, 202(3), 355-361.
Publication 2010
Adsorption Antibodies Biological Assay Birth Weight Blood Capsule CD4 Positive T Lymphocytes Cells Child Childbirth Eligibility Determination Enzyme-Linked Immunosorbent Assay Enzyme Immunoassay Gestational Age HIV-2 HL-60 Cells Immunization Programs Immunoglobulin G Infant Lamivudine lopinavir-ritonavir drug combination Meninges Mothers pathogenesis Pharmaceutical Preparations Pneumococcal Vaccine Polysaccharides Pregnancy Prevnar Respiratory Rate Response, Immune Serum Treatment Protocols Vaccination Vaccines Veins Voluntary Workers Zidovudine
3
Preventing HIV Transmission in Botswana
Cited 23 times
Between July 2006 and May 2008, we enrolled pregnant women with HIV-1 infection in the Mma Bana Study (meaning “mother of the baby” in Setswana) in southern Botswana. Women with CD4+ cell counts of 200 or more were randomly assigned (in permuted blocks stratified according to clinical site) to receive either 300 mg of abacavir, 300 mg of zidovudine, and 150 mg of lamivudine coformulated as Trizivir (GlaxoSmith-Kline) twice daily (the NRTI group) or 400 mg of lopinavir and 100 mg of ritonavir coformulated as Kaletra (Abbott) with 300 mg of zidovudine and 150 mg of lamivudine coformulated as Combivir (GlaxoSmithKline) twice daily (the protease-inhibitor group). Women with CD4+ cell counts of less than 200 cells per cubic millimeter or with an acquired immunodeficiency syndrome (AIDS)–defining illness received standard-of-care treatment for Botswana: 200 mg of nevirapine, 300 mg of zidovudine, and 150 mg of lamivudine twice daily (after a 2-week lead-in period of oncedaily nevirapine at a dose of 200 mg) (the observational group). Women in the randomized groups began to receive HAART between 26 and 34 weeks’ gestation and continued it through weaning or 6 months post partum (whichever occurred first), and women in the observational group began to receive HAART between 18 and 34 weeks’ gestation and continued treatment indefinitely. We report results for the primary end points at 6 months post partum.
Infants received single-dose nevirapine (6 mg) at birth and received zidovudine (4 mg per kilogram of body weight twice daily) from birth through 4 weeks. Women were counseled to exclusively breast-feed and to complete weaning 3 days before the 6-month study visit. Infants were provided free formula and foods from the time of weaning (whenever it occurred) through 12 months.
Study drugs were provided by GlaxoSmith-Kline (Trizivir and Combivir) and Abbott Pharmaceuticals (Kaletra), but these companies had no other role in the design of the study, the accrual or analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication. The Botswana government provided nevirapine, Combivir, additional medications, and some laboratory testing. The Health Research Development Committee of Botswana and the Human Subjects Committee of the Harvard School of Public Health approved the study protocol and amendments. An independent data and safety monitoring board reviewed safety and efficacy data approximately every 6 months. The full study protocol including the statistical-analysis plan, is available with the full text of this article at NEJM.org. All authors vouch for the completeness and veracity of the reported data and analyses and attest that the study as reported conforms with the protocol.
Shapiro R.L., Hughes M.D., Ogwu A., Kitch D., Lockman S., Moffat C., Makhema J., Moyo S., Thior I., McIntosh K., van Widenfelt E., Leidner J., Powis K., Asmelash A., Tumbare E., Zwerski S., Sharma U., Handelsman E., Mburu K., Jayeoba O., Moko E., Souda S., Lubega E., Akhtar M., Wester C., Tuomola R., Snowden W., Martinez-Tristani M., Mazhani L, & Essex M. (2010). Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana. The New England journal of medicine, 362(24), 2282-2294.
Publication 2010
abacavir Acquired Immunodeficiency Syndrome Antiretroviral Therapy, Highly Active Body Weight CD4+ Cell Counts Cells Childbirth Clinical Trials Data Monitoring Committees Combivir Cuboid Bone Food HIV-1 Homo sapiens Infant Infection Kaletra Lamivudine Lopinavir Mothers Nevirapine Pharmaceutical Preparations Pregnancy Pregnant Women Protease Inhibitors Ritonavir Trizivir Woman Zidovudine
4
Timing of ART in HIV-TB Co-Infection
Cited 18 times
The SAPiT study is a three arm, open-label, randomized controlled trial. After providing written informed consent, qualifying HIV-tuberculosis co-infected patients were randomized to one of three treatment arms in a 1:1:1 ratio in permuted blocks of six or nine with no stratification using sealed envelopes; Arm 1 - ART to be initiated within 4 weeks of starting tuberculosis treatment (early integrated treatment arm), Arm 2 - ART to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment (late integrated treatment arm) and Arm 3 - ART to be initiated within 4 weeks after completing tuberculosis treatment (sequential treatment arm).
All participants received adherence counselling, cotrimoxazole prophylaxis, and the same once daily ART regimen; didanosine (250mg if weight <60kg and 400mg if weight >60kg), lamivudine (300mg) and efavirenz (600mg). ART adherence was assessed monthly by pill counts (pills issued minus pills returned as a percentage of anticipated pill consumption). Regardless of trial arm assignment, participants could be initiated on ART at any time by PCZCDC clinicians, study clinicians or their personal physicians at their discretion.
Follow-up visits for safety and clinical status monitoring were scheduled monthly for 24 months. Adverse events were graded using the Division of AIDS (NIAID/NIH) Table for Grading Adult and Pediatric Adverse Events, version 1.0, 28 December 2004. CD4+ count using the FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes NJ, USA), HIV RNA (Roche Cobas Amplicor HIV-1 Monitor v1.5) were performed at screening, randomization and 6 monthly thereafter, while radiological changes and sputum conversion were monitored at screening, end of the intensive phase of tuberculosis treatment, one month before the end of tuberculosis treatment and whenever clinically indicated. Secondary endpoints included tolerability, toxicity, HIV RNA, tuberculosis outcomes and IRIS. IRIS was defined as a paradoxical deterioration in clinical status after ART initiation without another attributable cause.
Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., Gengiah T., Nair G., Bamber S., Singh A., Khan M., Pienaar J., El-Sadr W., Friedland G, & Karim Q.A. (2010). Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. The New England journal of medicine, 362(8), 697-706.
Publication 2010
Acquired Immunodeficiency Syndrome Adult CD4+ Cell Counts Contraceptives, Oral Didanosine efavirenz HIV-1 Iris Lamivudine Patients Physicians Safety Sputum Treatment Protocols Trimethoprim-Sulfamethoxazole Combination Tuberculosis X-Rays, Diagnostic
5
Timing of ART Initiation in HIV-TB Co-infection
Cited 16 times
This was a prospective, open-label, randomized trial in South Africa. A total of 642 ambulatory patients with pulmonary tuberculosis and HIV co-infection, aged 18 years or older, were enrolled after obtaining written informed consent.
Pulmonary tuberculosis was confirmed by acid fast bacilli smear positivity. HIV-infection was confirmed by two rapid HIV tests. All patients had a screening CD4+ count < 500 cells/mm3 and were initiated on a standard tuberculosis treatment regimen7 (link). All first episode tuberculosis patients were treated a fixed drug combination of rifampicin, isoniazid, ethambutol and pyrazinamide dosed according to pre-treatment weight for 2 months (intensive phase) with subsequent fixed-drug combination of isoniazid and rifampicin for 4 months (continuation phase) for all first episodes of tuberculosis. Patients with re-treatment tuberculosis received a 60 day intensive phase which includes streptomycin, followed by a 100 day continuation phase.
Details of the study methods have been previously reported 1 (link). The once daily antiretroviral therapy regimen contained enteric-coated didanosine (250mg if weight <60kg and 400mg if weight ≥60kg), lamivudine (300mg) and efavirenz (600mg). Antiretroviral therapy adherence was assessed monthly by pill counts. Notwithstanding their study group assignment, patients could be initiated on antiretroviral therapy at any time at the discretion of the study clinicians or their personal physicians.
The outcome of the sequential therapy group has been previously reported1 (link). This analysis comprises complete follow-up data on the 214 patients in the early integrated-therapy group (antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment) and the 215 patients in the late integrated-therapy group (antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment). The details of the study methods and data on 18 months follow-up of all three study groups are provided in the supplementary appendix (Supplementary Tables 1–3).
All analyses were by intention-to-treat. The trial’s primary outcome, AIDS or death rate, was analyzed using Kaplan–Meier curves. The duration of time in the study was calculated as the time from randomization to death or AIDS-defining illness, withdrawal from the study, or 18 months post randomization, whichever occurred first. Poisson approximations were used to calculate confidence intervals for the incidence rate ratios. Proportional-hazards regression was used to adjust for confounding variables. Fisher’s exact test was used for the analysis of categorical data, and unpaired t-tests or the Wilcoxon two-sample test for the analysis of continuous data. Interactions between therapy group and CD4+ count were evaluated by fitting a proportional hazards model with therapy group, CD4+ count and their interaction.
The trial (NCT00398996) was approved by the University of KwaZulu-Natal’s Biomedical Research Ethics Committee (E 107/05) and the Medicines Control Council (MCC ref: 20060157). Study data were reviewed periodically by a Safety Monitoring Committee.
Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A.L., Gengiah T., Gengiah S., Naidoo A., Jithoo N., Nair G., El-Sadr W.M., Friedland G, & Abdool Karim Q. (2011). Integration of Antiretroviral Therapy with Tuberculosis Treatment. The New England journal of medicine, 365(16), 1492-1501.
Publication 2011
Acquired Immunodeficiency Syndrome Bacillus acidicola CD4+ Cell Counts Cells Contraceptives, Oral Didanosine Drug Combinations efavirenz Ethambutol Ethics Committees, Research Group Therapy HIV Infections Isoniazid Lamivudine Patients Pharmaceutical Preparations Physicians Pyrazinamide Rifampin Safety Streptomycin Testing, AIDS Therapeutics Treatment Protocols Tuberculosis Tuberculosis, Pulmonary

Most recents protocols related to «Lamivudine»

1
ADMET Profiling of Chrysin and Lamivudine
The drug-likeness analysis was performed by admetSAR and SwissADME to confirm any cytotoxicity produced by ligands in humans. Several pharmacokinetics properties such as absorption, distribution, metabolism, excretion and toxicity (ADMET) of the tested compound chrysin and the positive control lamivudine were measured with the web tools admetSAR [37 (link)] and SwissADME [38 (link)]. The physicochemical properties were also studied with the help of these servers.
Bhat S.A., Hasan S.K., Parray Z.A., Siddiqui Z.I., Ansari S., Anwer A., Khan S., Amir F., Mehmankhah M., Islam A., Minuchehr Z, & Kazim S.N. (2023). Potential antiviral activities of chrysin against hepatitis B virus. Gut Pathogens, 15, 11.
Full text: Click here
Publication 2023
ADMET chrysin Cytotoxin Drug Kinetics Homo sapiens Lamivudine Ligands Metabolism Pharmaceutical Preparations
2
Structural Analysis of HMGB1 Protein
HMGB1 (PDB ID: 1AAB) is a signalling protein present in the nucleus. Its crystal structure was downloaded from protein data bank (http://www.pdb.org/). We removed the crystallographic water molecules or ligands, in order to produce a free receptor, and to enhance the entropy of the target. The missing polar hydrogen atoms were incorporated, and the energy level of target was minimized while using Swiss_PDB viewer tool. With the help of this server, we speculated the 3D structure of HMGB1 protein. Autogrid 4 module, a bioinformatics tool used to map the protein’s 3D structure, covered all the amino acid residues of the protein. The grid three dimensions X, Y and Z were fixed to be 50, 70 and 58 Å (receptor axis coordinates), and 0.405 Å as grid space size for lamivudine-HMGB1; and 52, 83 and 58 Å (receptor axis coordinates), and 0.435Å as grid space size for chrysin–HMGB1.
Bhat S.A., Hasan S.K., Parray Z.A., Siddiqui Z.I., Ansari S., Anwer A., Khan S., Amir F., Mehmankhah M., Islam A., Minuchehr Z, & Kazim S.N. (2023). Potential antiviral activities of chrysin against hepatitis B virus. Gut Pathogens, 15, 11.
Full text: Click here
Publication 2023
Amino Acids Cell Nucleus chrysin Crystallography Entropy Epistropheus HMGB1 Protein Hydrogen Lamivudine Ligands Proteins protein S, human Staphylococcal Protein A
3
Molecular Docking of Lamivudine and Chrysin
The molecular structure of lamivudine (positive control) and chrysin was drawn by ChemDraw12 (PerkinElmer Informatics, Waltham, MA, USA) as shown in Fig. 1A and B, respectively. The molecular structure of compounds was converted into 3D form, and geometries were optimized in ChemBio3DUltra12 (PerkinElmer Informatics, Waltham, MA, USA). For docking studies, the tested compound chrysin and positive control lamivudine was saved in PDB format. Molecular docking was performed by using Auto dock 4.2 in order to achieve better insights into the binding mechanism of chrysin and lamivudine with HMGB1. Docking guidelines were followed in this docking simulation. To achieve molecular docking, Lamarckian Genetic Algorithm (LGA) was used to define the best potential structures of the ligands that directly interacted with the target protein. Here the ligand was allowed free to explore and interact with the protein's active site in the best possible or threshold energy configuration. Ideal docked configurations were archived and studied for further interaction between receptor-ligand, employing BOVIA Discovery Studio 4.0 to generate 2D interaction plot [34 ]. Docking was eventually visualized by Pymol [35 (link)]. Lamivudine, a nucleoside analogue approved by FDA for the treatment of chronic hepatitis B virus infection, was also docked with the same protein. In the molecular docking analysis, lamivudine was used as a positive control. For protein–ligand interaction, the binding constant (Kb) was calculated using equation (∆G = − RTlnKb (R = universal gas constant, 1.987 kcal/mol/; T = temperature, 298 K) [36 (link)].

A and B represents optimized two-dimensional molecular geometries of anti-HBV compounds lamivudine (nucleoside analogue used as a reference drug in molecular docking analysis only) and chrysin respectively

Bhat S.A., Hasan S.K., Parray Z.A., Siddiqui Z.I., Ansari S., Anwer A., Khan S., Amir F., Mehmankhah M., Islam A., Minuchehr Z, & Kazim S.N. (2023). Potential antiviral activities of chrysin against hepatitis B virus. Gut Pathogens, 15, 11.
Full text: Click here
Publication 2023
chrysin Hepatitis B, Chronic HMGB1 Protein Lamivudine Ligands Molecular Structure Nucleoside Analogs Pharmaceutical Preparations Proteins Protein Targeting, Cellular Reproduction
4
In Silico Screening for Hepatitis B Treatments
In the present study in silico approaches were also used  to trace the active compounds against Hepatitis B virus. It is a convenient drug screening method, where the candidate drugs can be virtually examined at low cost in a short duration. This involves computational simulation of target-ligand interaction and regulates the perfect alignment of binding of one molecule to the second molecule to generate a stable complex. This method, called docking, is used to find the activity of binding of a tiny molecule (in this case, a drug candidate- chrysin, and a positive control lamivudine) to their protein target (in this case HMGB1) by using the scoring functions.
This screening method plays a pivotal role in the functional designing of drug candidates.
Bhat S.A., Hasan S.K., Parray Z.A., Siddiqui Z.I., Ansari S., Anwer A., Khan S., Amir F., Mehmankhah M., Islam A., Minuchehr Z, & Kazim S.N. (2023). Potential antiviral activities of chrysin against hepatitis B virus. Gut Pathogens, 15, 11.
Full text: Click here
Publication 2023
B virus, Hepatitis chrysin HMGB1 Protein Lamivudine Ligands Pharmaceutical Preparations Protein Targeting, Cellular
5
Antiretroviral Therapy in Suppressed HIV
We selected four study subjects enrolled in the Northwestern University Clinical Research Site for the MWCCS. The four men were well-suppressed patients who had received antiretroviral drugs for at least 5 years. Subject A received stavudine, tenofovir, lamivudine, and nevirapine; subject B received efavirenz, lopinavir, and tenofovir; subject C received ritonavir, amprenavir, and lamivudine/zidovudine; and subject D received indinavir and lamivudine at the sampling visits. We obtained PBMCs from cryostorage more than 5 years after starting antiretroviral therapy and undetectable plasma HIV-1 (<50 copies/ml). Laboratory procedures for clinical sample management are described elsewhere (82 (link)). The Institutional Review Board of Northwestern University approved the study (STU00022906-CR0008) with most recent approval date of 16 May 2022. All participants provided written informed consent.
Soliman S.H., Cisneros W.J., Iwanaszko M., Aoi Y., Ganesan S., Walter M., Zeidner J.M., Mishra R.K., Kim E.Y., Wolinsky S.M., Hultquist J.F, & Shilatifard A. (2023). Enhancing HIV-1 latency reversal through regulating the elongating RNA Pol II pause-release by a small-molecule disruptor of PAF1C. Science Advances, 9(10), eadf2468.
Publication 2023
amprenavir Clinical Laboratory Techniques efavirenz Ethics Committees, Research HIV-1 Indinavir Lamivudine lamivudine, zidovudine drug combination Lopinavir Nevirapine Patients Pharmaceutical Preparations Plasma Ritonavir Specimen Handling Stavudine Tenofovir Therapeutics

Top products related to «Lamivudine»

1
Lamivudine by Merck Group
Sourced in United States, Germany
Lamivudine is a laboratory equipment product manufactured by Merck Group. It is a nucleoside reverse transcriptase inhibitor (NRTI) used in the research and development of antiviral therapies.
2
Hot axios by Boston Scientific
Sourced in United States
The Hot AXIOS is a medical device designed for endoscopic drainage procedures. It features a hot needle that can create a full-thickness opening between two cavities or organs, allowing for the placement of a stent or catheter. The device is intended to facilitate the drainage of fluid collections or the creation of an anastomosis between two structures.
3
Gf uct180 by Olympus
Sourced in Japan, United States, Germany
The GF-UCT180 is an Olympus laboratory microscope designed for high-resolution imaging. It features a 180x magnification capability and utilizes an ultra-compact design.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
Lamivudine by GlaxoSmithKline
Sourced in China, United Kingdom
Lamivudine is a synthetic nucleoside analogue used in the manufacture of laboratory equipment. It functions as a reverse transcriptase inhibitor.
6
Acetonitrile by Merck Group
Sourced in Germany, United States, Italy, India, China, United Kingdom, France, Poland, Spain, Switzerland, Australia, Canada, Brazil, Sao Tome and Principe, Ireland, Belgium, Macao, Japan, Singapore, Mexico, Austria, Czechia, Bulgaria, Hungary, Egypt, Denmark, Chile, Malaysia, Israel, Croatia, Portugal, New Zealand, Romania, Norway, Sweden, Indonesia
Acetonitrile is a colorless, volatile, flammable liquid. It is a commonly used solvent in various analytical and chemical applications, including liquid chromatography, gas chromatography, and other laboratory procedures. Acetonitrile is known for its high polarity and ability to dissolve a wide range of organic compounds.
7
Hot axios stent by Boston Scientific
Sourced in United States
The Hot AXIOS stent is a medical device designed for endoscopic drainage procedures. It is a self-expanding, metal stent that is deployed using a delivery system. The stent is intended to create a connection between two hollow organs or structures within the body.
8
Lamivudine by LGC
Sourced in Canada
Lamivudine is a laboratory reagent used in various analytical applications. It is a nucleoside reverse transcriptase inhibitor (NRTI) that can be utilized in assays and research studies.
9
Methanol by Merck Group
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
10
Lipofectamine 2000 by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Lithuania, Hong Kong, Argentina, Ireland, Austria, Israel, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.

More about "Lamivudine"

Lamivudine, also known as 3TC, is a nucleoside reverse transcriptase inhibitor (NRTI) used to treat HIV infection and hepatitis B.
It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of the HIV and hepatitis B viruses.
Lamivudine is often used in combination with other antiretroviral drugs, such as Zidovudine (AZT) or Dolutegravir, to form a more effective treatment regimen for HIV.
It is also used as a treatment for chronic hepatitis B infection, either alone or in combination with other antiviral medications.
When researching Lamivudine, researchers may utilize related compounds and techniques, such as Hot AXIOS, GF-UCT180, FBS, Acetonitrile, Hot AXIOS stent, Methanol, and Lipofectamine 2000.
These substances and methods may be used in the development, testing, or analysis of Lamivudine-based treatments.
PubCompare.ai's AI-driven platform can help optimize Lamivudine research by enabling researchers to easily locate relevant protocols from literature, preprints, and patents.
The platform also utilizes AI-comparisons to identify the best protocols and products, streamlining the research process and helping to advance the understanding and development of Lamivudine-based therapies.